3/16
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Meetings
Low
Report
4DMT to Participate in Upcoming Investor Meetings
3/16
05:26 am
fdmt
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk [Yahoo! Finance]
Medium
Report
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk [Yahoo! Finance]
3/12
03:16 pm
fdmt
4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/6
01:50 pm
fdmt
4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [Seeking Alpha]
Low
Report
4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [Seeking Alpha]
2/28
02:39 am
fdmt
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? [Yahoo! Finance]
Medium
Report
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? [Yahoo! Finance]
2/19
08:00 am
fdmt
4DMT to Participate in Upcoming Investor Conferences
Low
Report
4DMT to Participate in Upcoming Investor Conferences
2/13
04:05 pm
fdmt
4DMT Announces New Employment Inducement Grants
Low
Report
4DMT Announces New Employment Inducement Grants
2/9
08:00 am
fdmt
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
Low
Report
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
2/2
10:00 am
fdmt
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]
Low
Report
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) [Yahoo! Finance]
1/28
08:03 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.
1/17
08:00 am
fdmt
4DMT Announces New Employment Inducement Grants
Low
Report
4DMT Announces New Employment Inducement Grants
1/7
03:02 pm
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/7
08:00 am
fdmt
4DMT Provides Company Update and Anticipated Development Milestones for 2026
Medium
Report
4DMT Provides Company Update and Anticipated Development Milestones for 2026
12/27
08:02 am
fdmt
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely [Yahoo! Finance]
Medium
Report
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely [Yahoo! Finance]
12/19
09:08 am
fdmt
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
Low
Report
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
12/18
08:05 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.
High
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.